PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie …
All news - Pipelinereview
6 days ago · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La …
Vaccines - Pipelinereview
LONDON, UK I November 21, 2024 I Vicebio Ltd (“Vicebio”), a biopharmaceutical company pioneering next-generation vaccines for life-threatening respiratory viruses, today announces …
DNA RNA and Cells - Pipelinereview
SINGAPORE I November 20, 2024 I Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based …
All news - Pipelinereview
Nov 18, 2024 · Collaboration will combine Vyriad’s lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation ROCHESTER, MN, USA I November 20, 2024 I …
Rona Therapeutics Presented Positive Phase 1 Results of RN0191, …
Nov 18, 2024 · Stella Shi, CEO of Rona Therapeutics, shared, “We are thrilled to report that RN0191 has demonstrated best-in-class PCSK9 siRNA potential. These results highlight …
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab …
Nov 19, 2024 · Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to …
About Us - Pipelinereview
The consultancy business of La Merie Business Intelligence was established in 2002 by Ulrich Martin, MD, based on his extensive experience in the biopharmaceutical industry both as a …
Proteins and Peptides - Pipelinereview
Oct 31, 2024 · Study DUS-AUBD-01 opens patient enrollment PRINCETON, NJ, USA I November 14, 2024 I Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage …
TREMFYA® (guselkumab) demonstrates impressive results across …
Oct 10, 2024 · TREMFYA ® is now U.S. FDA-approved for ulcerative colitis and under review for Crohn’s disease. TREMFYA ® is the only IL-23 inhibitor to demonstrate superiority to …